Quercetin supplementation for people with fibrotic interstitial lung disease
Official title: Study on the Efficacy of Quercetin Intake in Patients With Idiopathic Pulmonary Fibrosis and Non-Idiopathic Pulmonary Fibrosis. A Two-arm, Prospective Randomized Controlled Clinical Trial.
Run by University of Crete · NCT07466420 · Data updated 2026-11-12
This research will try whether taking 500 mg/day of quercetin in two 12-week cycles can change telomere length, reduce signs of cellular aging, and affect lung function in people with IPF and other fibrotic interstitial lung diseases.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University of Crete Academic / other |
| Locations | 1 site (Heraklion, Crete) |
| Status | Recruiting |
| Started | January 26, 2026 |
| Main results expected | January 31, 2028 |
| Study ends | January 31, 2029 |
| Registry record updated | March 12, 2026 |
| Trial ID | NCT07466420 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with a confirmed diagnosis of IPF or other fibrotic interstitial lung disease who can continue standard antifibrotic therapy and meet study screening criteria are appropriate candidates.
✕Probably not a fit
Patients with elevated exhaled nitric oxide (FeNO > 25 ppb), those unable to start quercetin within one week of baseline, or those unlikely to benefit from senolytic approaches may not receive benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, controlled trial enrolling 100 patients with idiopathic pulmonary fibrosis (IPF) or other fibrotic interstitial lung diseases to test oral quercetin versus usual care. Participants randomized to the quercetin arm will take 500 mg/day for two 12-week treatment cycles separated by an 8-week washout period, while all subjects may continue approved antifibrotic therapies. Primary biologic endpoints include telomere length and senescence-associated secretory phenotype (SASP) factors, with lung function measured over the treatment period. The trial is conducted at the Respiratory Department of the University Hospital of Heraklion, University of Crete.
Why it matters
Potential benefit: If successful, quercetin could lower markers of cellular senescence and help preserve or slow decline in lung function for patients with fibrotic ILDs.
How similar studies have gone: Preclinical work and small early-phase studies of senolytic combinations that include quercetin (often with dasatinib) have shown promising signals, but quercetin-alone trials in fibrotic lung disease are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with an established diagnosis of IPF and Fibrotic ILD and will be eligible to participate in the study. * The use of the approved standard of care antifibrotic therapy, either nintedanib or pirfenidone, and immunosuppressive therapy will be allowed as standard of care. Exclusion Criteria: * Subjects with a result of FeNO\>25 ppb will be excluded from the study to ensure that no other pulmonary diseases, such as asthma, are present. * Patients who do not initiate quercetin within the first week after their baseline visit.
Where it's running
-
Respiratory Department, University Hospital of Heraklion, School of Medicine, University of Crete
Heraklion, Crete, Greece Recruiting
Study contacts
- Principal investigator: Katerina M. Antoniou, MD PhD, Professor — Department of Respiratory Medicine, University Hospital of Heraklion, School of Medicine, University of Crete
- Study coordinator: Ioanna Argyriou, MSc
- Email: ioannaar07@gmail.com
- Phone: +302810371966
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Nerandomilast in IPF and Progressive Fibrosis: Real-World Data
This study tests whether nerandomilast helps slow lung function decline in adults with IPF or progressive fibrotic lung disease in routine clinical care.
-
Finger vs. Earlobe Pulse Oximetry During a 6-Minute Walk Test in ILD
This study tests whether finger or earlobe pulse oximetry gives the same oxygen saturation readings during a 6-minute walk in people with interstitial lung disease.
-
Measuring body fat and thigh muscle in people with pulmonary fibrosis starting anti-fibrotic drugs
This project will test whether quick bioelectrical impedance measurements and thigh muscle ultrasound can detect changes in body fat and muscle in adults with IPF or progressive pulmonary fibrosis who are starting anti-fibrotic medications.
-
Extension of inhaled antifibrotic treatment with AP01 for pulmonary fibrosis
This open-label extension lets people with progressive pulmonary fibrosis or IPF who finished a prior Avalyn inhaled-drug study continue taking inhaled pirfenidone (AP01) twice daily to see if they can tolerate and stay on treatment.
-
Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients
This observational study tests how fast patients with IPF or PPF can inhale through dry powder inhalers with different resistances.
-
Treprostinil Palmitil Inhalation Powder for Progressive Pulmonary Fibrosis
A 52-week study will test whether once-daily Treprostinil Palmitil Inhalation Powder helps lung function in adults with progressive pulmonary fibrosis compared to placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.